[Molecular profiling of non-small cell lung cancer]

Rev Pneumol Clin. 2014 Feb-Apr;70(1-2):47-62. doi: 10.1016/j.pneumo.2013.11.005. Epub 2014 Feb 22.
[Article in French]

Abstract

The management of locally advanced and metastatic non-small cell lung cancer has been revolutionized thanks to recent progress in pathology and molecular biology. The first molecular subgroup is defined by activating mutations of the epidermal growth factor receptor (EGFR), and a dramatic response to specific tyrosine kinase inhibitors. Since then, multiple genetic alterations (KRAS, HER2, BRAF, PIK3CA, ALK, ROS, RET…) have been identified as potential target of novel therapies, and molecular profiling has become common practice. This review focus on the molecular alterations associated with non-small cell lung cancer, including molecular profiling and response to targeted therapies.

Keywords: Adénocarcinomes du poumon; Biologie moléculaire; Molecular biology; Non-small cell lung cancer.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Decision Trees
  • Gene Expression Profiling
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Molecular Targeted Therapy
  • Mutation